First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT

Stereotaxis reports 100% clinical success in first human trial of Robocath’s new robotic system.

What the company is saying

Stereotaxis is highlighting the first-in-human clinical results for Robocath’s next-generation robotic system, presented at the TCT conference. The company emphasizes a 100% clinical success rate and a 95% technical success rate in a 20-patient pilot study for coronary artery disease, with no device-related complications through 30-day follow-up. The announcement stresses the absence of physician radiation exposure and the system’s ability to handle up to five devices simultaneously, suggesting advanced capability for complex procedures. Executives, including Chairman and CEO David Fischel, frame these results as validation of their innovation strategy and a milestone for robotic interventions. The company’s tone is confident, focusing on safety, efficacy, and workflow benefits, while also mentioning that a manuscript is under review and regulatory submissions are the next step. The narrative is forward-leaning, positioning Robocath as a technology leader and underscoring the potential for broader adoption.

What the data suggests

The disclosed data show that all 20 patients in the pilot study achieved minimal residual stenosis post-PCI, meeting the study’s clinical success criteria for a 100% rate. Technical success was achieved in 95% of cases, with only one procedure requiring conversion from robotic to manual. There were no device-related adverse events or major complications reported within a 30-day follow-up, indicating a strong safety profile. The study included a range of lesion complexities (A/B1, B2, and C-type), supporting claims of versatility. No quantitative data is provided on physician radiation exposure, but the procedures were performed with full protection from fluoroscopy radiation. Stereotaxis technology has been used in over 150,000 patients globally, but no new financial, revenue, or cost figures are disclosed. The evidence is robust for early clinical safety and efficacy, but the sample size is small and commercial or regulatory outcomes remain unproven.

Analysis

The announcement is upbeat, highlighting a 100% clinical success rate and a clean safety profile in a first-in-human pilot study of Robocath’s next-generation robotic system. The clinical data disclosed—success rates, patient numbers, and procedural complexity—are concrete and credible, supporting the claim of technical achievement at this early stage. However, the narrative is inflated by forward-looking statements about the system’s potential to reduce occupational risk, improve care, and advance toward regulatory submissions, none of which are realised or quantified. The benefits to patients, physicians, and the company’s commercial prospects are all projected into the future, with no timeline for regulatory approval or market launch. No financial or profitability metrics are disclosed, and there is no mention of capital outlay or immediate earnings impact. The gap between the company’s narrative and the evidence lies in the extrapolation from a small, early-stage clinical study to broad claims of future impact and commercial success.

Risk flags

• ●The pilot study’s small sample size (20 patients) limits the generalizability of the results, making it uncertain whether similar outcomes will be achieved in larger, more diverse populations.
• ●Regulatory approval is not yet secured; the company only states that submissions are planned, so there is execution risk in advancing from pilot data to commercial clearance.
• ●No financial or commercial data is disclosed, leaving investors without visibility on cost structure, pricing, reimbursement, or market adoption, which are critical for assessing future value.
• ●Forward-looking statements about potential benefits and regulatory progress are not backed by concrete milestones or timelines, increasing the risk that projected advantages may not materialize as anticipated.

Bottom line

Stereotaxis delivers promising early clinical results for its Robocath next-generation robotic system, with 100% clinical and 95% technical success in a 20-patient pilot study and no device-related complications at 30 days. The data support the system’s technical feasibility and safety in a controlled setting, but the announcement does not address regulatory status, commercial readiness, or financial impact. All forward-looking claims about broader adoption, physician safety, and market potential remain speculative until larger trials and regulatory submissions are completed. Investors should recognize that while the clinical evidence is encouraging, the pathway to revenue and commercial value is still at an early stage. The most important takeaway is that Stereotaxis has cleared an initial clinical hurdle, but substantial execution and regulatory risks remain before any commercial upside can be realized.

Announcement summary

(NYSE: STXS) Stereotaxis announced the first-in-human clinical results for Robocath’s next-generation robotic system at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. The study was conducted by Dr. Mohammed Nejjari and Dr. Franck Digne, Interventional Cardiologists at Centre Cardiologique du Nord (CCN) in Saint-Denis, France. This prospective pilot clinical study enrolled twenty patients undergoing percutaneous coronary intervention (PCI) for coronary artery disease. The study achieved a 100% clinical success rate, with all 20 patients meeting the clinical success criteria of minimal residual stenosis post PCI. Technical success was 95%, as all but one procedure were completed entirely robotically without conversion to manual. There were no device-related adverse events, with a clean safety profile reported through 30-day follow-up, including no intra-procedural vascular complications or major adverse events. Operating physicians performed the procedures entirely protected from fluoroscopy radiation, indicating no physician radiation exposure and supporting the system’s potential to reduce occupational risk. The study included A/B1, B2, and C-type lesions, representing three levels of procedural complexity, including complex coronary disease in tortuous distal vasculature. Dr. Nejjari presented these findings during the November 1, 2026 scientific session “Innovations in Robotics for Transcatheter Heart Interventions” at TCT. A manuscript documenting the findings has been submitted for publication and is under review. Robocath, a subsidiary of Stereotaxis, is described as a technology leader in advanced robotic innovations for interventional cardiology and neurointerventions. The next-generation system adds advanced capabilities such as multi-device handling of up to five interventional devices simultaneously to support increasingly complex procedures. David Fischel, Chairman and CEO of Stereotaxis, stated that these results support confidence in the company’s innovation strategy and reflect a commitment to advancing differentiated robotic technologies across endovascular interventions. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.

Disagree with this article?